Determination of myricetin derivatives in Chrysobalanus icaco L. (Chrysobalanaceae) by BARBOSA, Wagner Luiz Ramos et al.
333
A
rti
go
ISSN 0102-695X
Received 12/18/05. Accepted 06/27/06
* E-mail: barbosa@ufpa.br, Tel. + 55-91-32017204
Revista Brasileira de Farmacognosia
Brazilian Journal of Pharmacognosy
16(3): 333-337, Jul./Set. 2006
Determination of myricetin derivatives in Chrysobalanus icaco L. 
(Chrysobalanaceae)
Wagner Luiz R. Barbosa1*, Amiraldo Peres1, Sandra Gallori2, Franco F. Vincieri2
1Laboratório de Fitoquímica e Cromatografi a Líquida de Alta Efi ciência, Departamento de Farmácia, Universidade 
Federal do Pará, 66075-110, Belém, Pará, Brasil,
2Dipartimento di Scienze Farmaceutiche, Univeristà degli Studi di Firenze, Polo Scientifi co di Sesto Fiorentino, Via 
U. Schiff 6, 50100 Firenze, Italy
RESUMO: “Determinação de derivados de miricetina em Chrysobalanus icaco L. 
(Chrysobalanaceae)”. A fração fl avonoídica do extrato hidroalcoólico de folhas de Chrysobalanus 
icaco L. (Chrysobalanaceae), que são largamente utilizadas na medicina tradicional do Norte 
do Brasil para controlar a glicemia de pacientes diabéticos, foi caracterizada. Miricetina-3-O-
glucuronídeo (miricitrina) e quercitrina, entre outros derivados de miricetina minoritários, foram 
evidenciados por análises com sistemas CLAE/DAD e CLAE/EM.
Unitermos: Chrysobalanus icaco, Chrysobalanaceae, miricetina, medicina tradicional, diabetes.
ABSTRACT: The fl avonoidic fraction composition of the hydroalcoholic extract of Chrysobalanus 
icaco L. (Chrysobalanaceae) leaves, which are largely used in the traditional medicine in Northern 
Brazil to control the glycaemia of diabetic patients, was characterised. Myricetin 3-O-glucuronide 
(miricitrin) and quercitrin, among other minor myricetin derivatives, were evidenced by HPLC/
DAD and HPLC/MS analysis.
Keywords: Chrysobalanus icaco, Chrysobalanaceae, myricetin, traditional medicine, diabetes.
INTRODUCTION
  Chrysobalanus icaco L., also known as “coco 
plum”, “icaco”, “agirú”, is an evergreen, medium-sized 
shrub or, rarely, a small tree with leathery, dark-green, 
round to oval leaves. The species is native to coastal 
areas of southern Florida, the Bahamas and through the 
Caribbean. It is also found through Central and South 
America, including Mexico, Ecuador and Northern Brazil 
as well as tropical Africa (Little et al., 1974).
 The aqueous extract of Chrysobalanus icaco L. 
leaves (Chrysobalanaceae family) is commonly used in 
the traditional medicine in northern Brazil (State of Pará) 
to control the glycaemia of diabetic patients (Barbosa et 
al., 2001; Costa, 1977; Pereira, 1997; Barbosa-Filho et 
al., 2005).
  To our knowledge only a few papers in the 
literature focus on the phytochemical investigation of 
Chrysobalanus icaco L. (Chaffaud; Emberger, 1960; 
Bate-Smith, 1961; Mendez et al., 1995; Coradin et al., 
1985;  Gunstone; Subbarao 1967;  Verma; Raychaudhuri, 
1972; Fernandes et al.,  2003; Gustafson; Munro, 
1991). The fi rst phytochemical investigations reports 
the presence of myricetin in Chrysobalanus icaco L. 
(Chaffaud; Emberger, 1960) leaves. Thus, myricetin 
(Figure 1) is considered a primitive fl avonoid character 
and its presence has been used as a chemotaxonomic 
marker in the Chrysobalanaceae family (Mendez et al., 
1995; Coradin et al., 1985). In earlier works trienoic, 
tetraenoic acids and their oxo derivatives in seed oils 
(Gunstone; Subbarao 1967) and catechol tannins (Verma; 
Raychaudhuri, 1972) were found. Finally, the presence of 
diterpenes and triterpenes in the leaves of Chrysobalanus 
icaco L. were also reported (Fernandes et al.,  2003; 
Gustafson; Munro, 1991). 
  HPLC has been effective in the analysis of 
fl avonoids of plant extracts (Yariwake et al., 2005). A 
preliminary analysis, by HPLC-DAD, of Chrysobalanus 
icaco L. leaves showed the presence of rutin in the 
aqueous extract and tincture (Barbosa; Peres, 2002). To 
continue our studies on this plant, the hydroalcoholic 
extract of Chrysobalanus icaco L. leaves was investigated. 
Myricetin 3-O-glucuronide and other myricetin and 
quercetin derivatives were identifi ed by HPLC/DAD and 
HPLC/MS analysis.
  Traditionally C. icaco is used as an infusion but 
to be used in the pharmaceutical manipulation a tincture 
has more suitable physical and chemical properties. Once 
the results here reported can be useful for the registration 
of this plant species as a phytotherapeutic medicine 
according to the Brazilian Health Regulation we decide 
to investigate the tincture, whit an alcoholic content 
corresponding to 70 degree Gay Lussac.
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MATERIAL AND METHODS
Plant material
  The Chrysobalanus icaco L. leaves were 
collected near to Belém (Pará, Brazil) in 2003. The plant 
material were identifi ed by Dr. Mário Augusto Gonçalves 
Jardim of the Museu Paraense Emilio Goeldi in Belém, 
Pará and a voucher specimen is deposited under the 
number LAFQ-005 at the Laboratório de Fitoquímica e 
Cromatografi a Líquida de Alta Efi ciência, Departamento 
de Farmácia, Universidade Federal do Pará, Belém, Pará, 
Brasil.
Chemicals
   CH3CN and MeOH (HPLC grade) were from 
Merck (Darmstadt, Germany); 85% formic acid was 
provided by Carlo Erba (Milan, Italy). Water was purifi ed 
by a Milli-Qplus system from Millipore (Milford, MA, 
USA). 0.45 μm PTFE membrane fi lter was purchased 
from Waters Co. (Milford, MA). All laboratory chemicals 
used in this study were of reagent grade. Quercetin and 
quercetin 3-O-rhamnoside (quercitrin) authentic standards 
were purchased from Extrasynthese S.A.
Sample preparation
  20g Dried and grounded leaves of Chrysobalanus 
icaco were extracted by maceration for 3 days with 200 
mL ethanol 70 °GL to give the hydroalcoholic extract. 
The obtained tincture (200 mL) was evaporated under 
vacuum and lyophilized to dryness to give 1.95 g of a 
greenish yellow powder. 50 mg of this sample were 
rinsed with 2 mL of MeOH, then fi ltered through a 0.45 
μm PTFE fi lter into HPLC vials directly and analysed by 
HPLC-DAD and HPLC-MS.
Instrumentation and conditions
HPLC-DAD analyses were performed on a HP 
1090L Series II liquid chromatograph equipped with a 
diode array detector (all from Hewlett & Packard, Palo 
Alto, CA, USA). Columns were 250 x 4.6 mm Synergy 
MAX RP-12 (4μ) (Phenomenex®, USA) and 250 x 4.6 
mm LiChroCART® Purosphere STAR RP-18 (4μ). The 
oven column was maintained at 26 °C.
The compounds were separated using H2O 
(adjusted to pH 3.2 by HCOOH), CH3CN and MeOH; 
the applied linear solvent gradient is reported in Table 1. 
UV-Vis spectra were recorded in the range 190-450 nm, 
and the chromatograms were acquired at  230, 254, 280, 
330 and 350 nm. 
Mass spectra were performed using a HP 
1100 MSD API-electrospray coupled with a HP 1100L 
liquid chromatograph equipped with a DAD detector 
(Hewlett & Packard, Palo Alto, CA, USA). The interface 
geometry, with an orthogonal position of the nebulizer 
with respect to the capillary inlet, allowed the use of 
analytical conditions similar to those of HPLC-DAD 
analysis. The same column, mobile phase, time period 
and fl ow rate were used. Mass spectrometry operating 
conditions were optimised in order to achieve maximum 
sensitivity values: negative and positive ionisation mode 
(scan spectra  from m/z 100 to 800) were used with a gas 
temperature of 350 °C, nitrogen fl ow rate of 10.0 L/min, 
nebulizer pressure 30 psi, quadrupole temperature 30 °C, 
and capillary voltage 3500 V. The applied fragmentors 
were in the range 80-150 V. The orthogonal position of 
the nebulizer with respect to the capillary inlet allowed 
the use of the same conditions of HPLC/DAD analysis 
with H2O adjusted to pH 3.2 by HCOOH.
RESULTS AND DISCUSSION
  Identifi cation of constituents was carried out 
by HPLC/DAD and HPLC/MS analysis, and/or by 
comparison and combination of their HPLC retention 
times, UV-Vis and mass spectra with those of authentic 
samples and by comparison with the chromatogram 
obtained of a fully characterised extract of Pistacia 
lentiscus L. (Romani et al., 2002). For the characterisation 
of the compounds, the HPLC/MS analysis in negative 
and positive ion mode, applying different fragmentation 
energy, was a very useful tool.   
  The chromatographic profi le reported in Figure 
2, acquired at 350 nm, relative to the total hydroalcoholic 
extract from Chrysobalanus icaco L. leaves revealed 
the presence of several fl avonoid derivatives such as 
myricetin 3-O-glucuronide, miricitrin and quercitrin, 
among other myricetin derivatives.
  The peak recorded at Rt 24.33 min showed two 
major signals in the mass spectra: the peak corresponding 
to the quasi-molecular ion [M-H]- at m/z 493 and the 
fragment ion at m/z 317 corresponding to the loss 
of glucuronic acid (Figure 3). By UV-Vis and mass 
spectra this compound was identifi ed as myricetin 3-O-
glucuronide and represents the major compound present 
in the extract.
  The peak recorded at Rt 16.48 min showed two 
major signals in the mass spectra: the peak corresponding 
to the quasi-molecular ion [M-H]- at m/z 625 and the 
fragment ion at m/z 317 corresponding to the loss 
of rhamnose unit. By UV-Vis and mass spectra this 
compound was identifi ed as myricetin 3-O-rutinoside.
  By UV-Vis, mass spectra and by comparison of 
the rutin authentic sample, the peak recorded at Rt 19.63 
min was identifi ed as rutin. These data confi rmed the 
presence of rutin, previously identifi ed in Chrysobalanus 
icaco L. (Barbosa; Peres, 2002).
  The peak recorded at Rt 21.02 min showed 
two major signals in the mass spectra: the peak 
corresponding to the quasi-molecular ion [M-H]- at m/
z 463 and the fragment ion at m/z 317 corresponding to 
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Figure 1. Structure of myricetin.
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Figure 2. HPLC chromatograms acquired at λ 350 nm of total hydroalcoholic extract of Chrysobalanus icaco L. leaves (column 
250 x 4.6 mm Synergy MAX RP-12 (4μ), Phenomenex®, USA).*Myricetin derivatives, ** Quercetin derivatives.
the loss of rhamnose unit. By UV-Vis, mass spectra and 
by comparison of the miricitrin authentic sample, this 
compound was identifi ed as myricetin-3-O-rhamnoside 
(miricitrin).
  The peak recorded at Rt 25.77 min showed 
two major signals in the mass spectra: the peak 
corresponding to the quasi-molecular ion [M-H]- at m/
z 447 and the fragment ion at m/z 301 corresponding to 
the loss of rhamnose unit. By UV-Vis, mass spectra and 
by comparison of the quercitrin authentic sample, this 
compound was identifi ed as quercetin 3-O-rhamnoside 
(quercitrin).
  Myricetin 3-O-rutinoside, myricetin 3-O-
rhamnoside, myricetin 3-O-glucuronide and quercetin 
3-O-rhamnoside were also detected by comparison of 
Chrysobalanus icaco L. extract with a sample of Pistacia 
lentiscus L. extract where these compounds were 
previously identifi ed (Romani et al., 2002).
  Moreover, from the UV spectra and MS data, 
the presence of other myricetin derivatives i.e. myricetin 
bonded with a pentose unit and glucuronic acid (Rt 19.06 
min), myricetin bonded with a pentose unit and rhamnose 
(Rt 20.69 min and Rt 21.23 min); quercetin derivatives 
i.e. quercetin bonded with a pentose unit and rhamnose 
(Rt 25.29 min); and a quercetin glucuronic derivative (Rt 
28.69 min) can be supposed (Figure 2).
  Finally, as a further investigation on the presence 
of  myricetin 3-O-glucuronide a LC-DAD and LC-MS 
analyses were also performed using a LiChroCART® 
Purosphere STAR RP-18 column with the same analytical 
parameters of the previous HPLC analyses. Figure 4 
shows the optimised chromatogram, acquired at 350 nm, 
with the main peak at Rt 22.34 min corresponding to 
myricetin 3-O-glucuronide, as the mass spectrum allows 
us to deduce.
CONCLUSION
  Using the LC-DAD-MS method, the presence 
of myricetin-3-O-glucuronide (miricitrin, as major 
constituent), quercitrin, and rutin, as well as other minor 
myricetin and quercetin derivatives in the hydroalcoholic 
extract of Chrysobalanus icaco L. leaves have been 
evidenced.
  Using the Star® (RP-18) column, we observed 
a shift of Rts with respect to the Synergy MAX (RP-
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Figure 3. Mass spectrum of myricetin 3-O-glucuronide at different points of the peak to assess peak 
min10 20 30 40
mAU
0
200
400
600
800
 DAD1 A, Sig=350,4 Ref=598,4, TT (ICACO\ICACO1.D)
 2
0.
12
0
 2
1.
32
4
 2
2.
34
0
 2
4.
04
0
 2
4.
78
6
 2
5.
07
1
 2
7.
02
4
 2
7.
66
7
 2
9.
37
3
 2
9.
93
0
 3
4.
28
9
 3
6.
11
4
Figure 4. HPLC chromatograms acquired at λ 350 nm of total hydroalcoholic extract of Chrysobalanus icaco L. leaves (column 
250 x 4.6 mm LiChroCART® Purosphere STAR RP-18 (4μ)
12) column. In particular, myricetin 3-O-glucuronide 
showed the most signifi cant change. This could be due 
to the structure of myricetin 3-O-glucuronide which can 
decrease the strength of interaction with more lipophilic 
substrates such as the Star® (RP-18) column phase with 
respect to MAX (RP-12) due to the presence of the 
glucuronic acid moiety. The other compounds showed, 
more or less, the same relationship of Rts obtained with 
the Synergy MAX column.
  The large presence of myricetin derivatives 
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in Chrysobalanus icaco L. leaves may also have an 
interesting ecological signifi cance because its presence 
has been used as chemotaxonomic marker in the 
Chrysobalanaceae family (Mendez et al., 1995; Coradin 
et al., 1985).
  Through the years, several studies have been done 
to investigate the various therapeutic biological effects 
of myricetin, including its use as a potent antioxidant, 
as an anticarcinogenic and antimutagenic agent, in the 
prevention of platelet aggregation, in cardiovascular 
diseases, antimicrobial properties against different 
bacterial strains, etc. (Kian et al., 1997). Myricetin 
derivatives have also been suggested to exhibit other 
relevant pharmacological activities such as those related 
to the generation of phenoxyl radicals in the inhibition of 
lipid peroxidation in rat hepatocyte culture (Morel et al., 
1998; Aherne; O’Brien, 1999). 
  Finally, it was shown that myricetin has both 
a hypoglycaemic and hypotriglyceridemic effect in 
diabetic animals (Ong; Khoo, 2000) and could thus be of 
therapeutic value in diabetes. These data can explain the 
traditional use of Chrysobalanus icaco L. leaves.
ACKNOWLEDGEMENTS
  We thank Dr. Mario Augusto Gonçalves Jardim 
Museu Paraense Emilio Goeldi, Belém, Pará, Brazil, for 
the identifi cation of the plant material.
REFERENCES
Aherne SA, O’Brien NM 1999. The fl avonoids, myricetin, 
quercetin and rutin, protect against cholestan-
3β,5α,6β-triol-induced toxicity in Chinese hamster 
ovary cell in vitro. Nutr Res 19: 749-760.
Barbosa WLR, Lima AP, Pinto LN 2001. Levantamento 
etnofarmacêutico da fi toterapia tradicional de 
Igarapé Mirí – Pará. VII Reunião Especial da 
Sociedade Brasileira para o Progresso da Ciência, 
Manaus, AM.
Barbosa WLR, Peres A 2002. Detecção e caracterização por 
cromatografi a líquida de alta efi ciência de rutina em 
extratos de Chrysobalanus icaco L. XVII Simpósio 
de Plantas Medicinais do Brasil, Cuiabá, MT.
Barbosa-Filho JM, Vasconcelos THC, Alencar AA, Batista LM, 
Oliveira RAG, Guedes DN, Falcão HS, Moura MD, 
Diniz MFFM, Modesto-Filho J 2005. Plants and 
their active constituents from South, Central, and 
North America with hypoglycemic activity. Rev 
Bras Farmacogn 15: 392-413.
Bate-Smith EC 1961. Chromatography and taxonomy in the 
Rosaceae, with special reference to Potentilla and 
Prunus. J Linn Soc London Bot 58: 39-54.
Chaffaud M, Emberger L 1960. Traite’ de Botanique 
Systematique Vol. II, Masson, Paris.
Costa OA 1977. Brazilian plants with hypoglycaemic effects. 
Leandra 7: 63-75.
Coradin L, Giannasi DE, Prance AT 1985. Chemosystematic 
studies in the Chrysobalanaceae. Flavonoids in 
Parinari. Brittonia 37: 169-178.
Fernandes J, Castilho RO, Costa MR, Souza KW, Kaplan 
MAC, Gattass CR 2003. Pentacyclic triterpenes 
from Chrysobalanaceae species: cytotoxicity on 
multidrug resistant and sensitive leukaemia cell 
lines. Cancer Lett 190: 165-169.
Gunstone FD, Subbarao R 1967. New tropical seed oils. Part 
I. conjugated trienoic and tetraenoic acids and their 
oxoderivatives in the seed oils of Chrysobalanus 
icaco and Parinarium laurinum. Chem Phys Lipids 
1: 349-359.
Gustafson KR, Munro MHG 1991. HIV inhibitory natural 
products: 3. Diterpenes from Homalanthus 
acuminatus and Chrysobalanus icaco. Tetrahedron 
47: 4547-4554.
Kian C, Ong KC, Khoo HE 1997. Biological effects of myricetin 
(Review). Gen Pharmacol 29: 121-126.
Little EL-Jr, Woodbury RO, Wadswort FH 1974. Trees of Puerto 
Rico and the Virgin Islands, Agriculture Handbook 
449, Vol.2. Washington, DC: U.S. Department of 
Agriculture.
Mendez J, Bilia AR, Morelli I 1995. Phytochemical 
investigations of Licania genus. Flavonoids and 
triterpenoids from Licania pittieri. Pharma Acta 
Helv 223-226.
Morel I, Abalea V, Sergent O, Cillard P, Cillard J 1998. 
Involvement of phenoxyl radical intermediates in 
lipid anti-oxidant action of myricetin in iron-treated 
rat hepatocyte culture. Biochem Pharmacol 55: 
1399-1404.
Pereira NA 1997. Plants as hypoglycaemic agents. Ciência e 
Cultura 49: 354-358.
Ong KC, Khoo HE 2000. Effects of myricetin on glycaemia 
and glycogen metabolism in diabetic rats. Life Sci 
1695-1705. 
Romani A, Pinelli P, Galardi C, Mulinacci N, Tattini M 
2002. Identifi cation and quantifi cation of galloyl 
derivatives, fl avonoid glycosides and anthocyanins 
in leaves of Pistacia lentiscus L. Phytochem Anal 
13: 79-86.
Verma VS, Raychaudhuri SP 1972. Effect of catechol tannins 
isolated from a medicinal plant Chrysobalanus 
icaco on the infectivity of potato virus X. Zentralbl 
Bakteriol Parasitenkd Infektionskr Hyg 127: 178-
179.
Yariwake JH, Lanças FM, Cappelaro EA, Vasconcelos EC, 
Tiberti LA, Pereira AMS, Franca SC 2005. 
Variabilidade sazonal de constituintes químicos 
(triterpenos, fl avonóides e polifenóis) das folhas 
de Maytenus aquifolium Mart. (Celastraceae). Rev 
Bras Farmacogn 15: 162-168.
